Repeatability and Response Study of Absorptive Clearance Scans

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2018-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators are developing a new nuclear medicine imaging technique for measuring liquid absorption in the airways that can be applied to screen new medications being developed to treat cystic fibrosis (CF). The investigators believe that the absorption of the small molecule radiopharmaceutical Indium 111 diethylene triamine pentaacetic acid (In-DTPA) will indicate changes in liquid absorption in the airways and demonstrate whether new CF medications will be effective. In this study the investigators will determine whether the imaging technique will demonstrate similar results when it is repeated on different days. They will also determine how their results change when subjects utilize several common CF medications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Imaging Airway Liquid Absorption in Cystic Fibrosis

NCT01486199

Cystic Fibrosis

COMPLETED NA

Absorptive Clearance in the Cystic Fibrosis Airway

NCT00541190

Cystic Fibrosis

COMPLETED NA

Multilevel Models of Therapeutic Response in the Lungs

NCT02947126

Cystic Fibrosis

COMPLETED PHASE1

Assessing Mucociliary Clearance and Airway Liquid Volume in the CF Airway

NCT00248755

Cystic Fibrosis

COMPLETED NA

Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis

NCT01223183

Cystic Fibrosis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cystic Fibrosis (CF) is an autosomal recessive genetic disease, caused by mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) that impairs ion transport at epithelial surfaces. This results in the accumulation of dehydrated secretions in the airways and chronic infection and inflammation in the lungs, leading to significant morbidity and mortality. The investigators understanding of CF pathogenesis has increased substantially and many new targeted therapies are being developed to treat this disease, however, the measurements of clinical efficacy used to evaluate these therapies require long trials to demonstrate an effect. New translational techniques are needed to assess changes in the most basic aspects of the disease and allow for the rapid screening of disease-altering therapies. The investigators have recently developed a novel aerosol-based imaging technique to measure liquid absorption in the airways - a central pathophysiological process related to CFTR dysfunction. The investigators propose that airway liquid hyper-absorption is a key link between cellular defects in ion and fluid transport and progressive airway dysfunction in CF. Thus The investigators technique may provide a measure of disease severity and rapid indication of therapeutic correction in advance of currently available outcome measures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Repeatability

Subjects perform two sequential absorptive clearance scans (within 30 days) to determine the repeatability of the technique. Subjects also perform a third scan two years later so that longitudinal change can be measured.

Group Type EXPERIMENTAL

Absorptive clearance scan

Intervention Type OTHER

Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.

Response

Subjects perform three different absorptive clearance scans. One is a baseline measurement while the other two measure absorptive clearance after an intervention (inhaled hypertonic saline, mannitol inhalation powder).

Group Type EXPERIMENTAL

Absorptive clearance scan

Intervention Type OTHER

Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.

inhaled hypertonic saline (7%)

Intervention Type DRUG

nebulized hypertonic saline (7%)

mannitol inhalation powder

Intervention Type DRUG

mannitol inhalation powder

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Absorptive clearance scan

Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.

Intervention Type OTHER

inhaled hypertonic saline (7%)

nebulized hypertonic saline (7%)

Intervention Type DRUG

mannitol inhalation powder

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Hypersal Bronchitol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* subjects 18 years old or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator

Exclusion Criteria

* one second forced expiratory volume (FEV1) \<50% of predicted
* nursing mother
* positive urine pregnancy test or unwilling to test
* cigarette smoker
* unwilling to stop hypertonic saline therapy for 72 hours prior to each test day
* are intolerant to hypertonic saline (response only)
* are intolerant to any inhaled therapies (response only)
* fail mannitol tolerance testing (response only)
* have a history of excessive (uncontrollable) coughing after an osmotic stimulus (response only)
* have a history of hemoptysis (response only)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No